Archives
Antibacterial Use and Resistance Patterns in Psychiatric Hos
2026-07-17
Antibacterial Drug Use and Bacterial Resistance in Psychiatric Hospitals During the Epidemic
Study Background and Research Question
Antibiotic resistance remains a critical global health challenge, especially within institutionalized environments where infection risks are amplified. Psychiatric hospitals occupy a unique niche due to patient vulnerabilities, such as compromised immune function and communal living arrangements, which can facilitate the spread of bacterial infections. During the COVID-19 epidemic, these factors were further complicated by increased infection control pressures and the need for prudent antimicrobial use. The reference study (Jiang et al., 2025) set out to analyze patterns of antibacterial drug use and bacterial resistance within a psychiatric hospital during the 2022 epidemic, aiming to inform more effective antimicrobial stewardship strategies for similar specialized settings.Key Innovation from the Reference Study
The central innovation of Jiang et al.'s work lies in its institution-specific, data-driven approach to monitoring both antibiotic consumption and resistance profiles during a major epidemic. Rather than relying solely on broad national or regional statistics, the authors retrospectively evaluated granular data from their hospital information system and the National Antibacterial Drug Clinical Application Monitoring Network. This enabled the identification of unique resistance trends and usage patterns specific to the psychiatric hospital context, which often differ from those of general medical or surgical wards. Crucially, the study highlighted the interplay between relatively low antibiotic use rates and the emergence of resistant strains, revealing that even conservative prescribing does not fully mitigate resistance risks in vulnerable populations.Methods and Experimental Design Insights
Jiang et al. conducted a retrospective analysis using data collected from the hospital's information system and the national antimicrobial monitoring network. The key methodological steps included:- Extracting 2022 data on antibiotic use rates, intensity (AUD), combination therapy frequency, cumulative defined daily doses (DDDs), and cost ratios.
- Reviewing the rate of microbiological testing associated with antibiotic use, which in this hospital was 77.78%, notably higher than provincial and national averages.
- Cataloguing the main antibiotics used: third-generation cephalosporins (notably cefodizime), penicillins (including amoxicillin), and quinolones (such as ciprofloxacin).
- Analyzing bacterial isolates and resistance patterns through positive pathogen identification and drug sensitivity testing.
Core Findings and Why They Matter
The study reported an antibiotic use rate of 5.00%, usage intensity of 3.07, combination therapy rate of 11.11%, with cumulative DDDs totaling 12,039.04 and antibiotic costs constituting 3.95% of total drug expenditures (Jiang et al., 2025). These rates were substantially lower than those observed across Jiangsu Province and nationally, suggesting commendable adherence to stewardship principles within the psychiatric hospital. However, the high rate of microbiological submission indicates a proactive approach to guiding therapy and tracking resistance. Despite conservative antibiotic utilization, both Gram-negative and Gram-positive bacteria demonstrated notable resistance to commonly used agents. Gram-negative isolates were largely resistant to penicillins, cephalosporins, and quinolones—particularly ampicillin, amoxicillin–clavulanic acid, ceftazidime, ceftriaxone, amikacin, and ciprofloxacin. Gram-positive isolates exhibited resistance to penicillins, macrolides, and quinolones, with penicillin, benzylpenicillin, erythromycin, levofloxacin, and ciprofloxacin among the most affected. These findings underscore the complexity of resistance dynamics, where prudent antimicrobial use alone may not suffice to curb the emergence of multi-drug resistant organisms in high-risk environments. The study provides strong evidence for the necessity of ongoing resistance surveillance and data-driven optimization of antimicrobial protocols in psychiatric hospitals. Enhanced microbiological testing, as practiced in this institution, offers a template for early detection and targeted intervention, potentially improving prognosis and reducing healthcare costs associated with resistant infections.Comparison with Existing Internal Articles
Several internal resources expand on key aspects identified in the reference paper, enriching the context for researchers interested in anti-inflammatory and antimicrobial research. For example, the article "Antibacterial Use and Resistance Patterns in Psychiatric Hospitals During Epidemics" corroborates the need for ongoing surveillance and multi-faceted stewardship, aligning closely with Jiang et al.'s recommendations. Additionally, research into lipid mediators such as Gamma-linolenic acid (GLA), an omega-6 polyunsaturated fatty acid with anti-inflammatory properties, has explored alternative or adjunctive strategies for modulating infection-related inflammation and cellular responses in disease models. Studies such as "Gamma-linolenic Acid (GLA, C5518): Mechanism, Benchmarks..." describe how GLA can serve as a weak leukotriene B4 receptor antagonist, offering additional pathways for controlling inflammatory signaling and potentially impacting host-pathogen interactions, as might be relevant in the context of multi-drug resistance and immune modulation.Limitations and Transferability
The reference study's retrospective, single-institution design limits the generalizability of its findings. While the detailed dataset enables robust internal comparisons and process improvements, the unique patient demographics and management style of a psychiatric hospital during an epidemic may not be directly transferable to other healthcare settings. Additionally, the study did not explore the clinical outcomes associated with specific resistance patterns, nor did it examine the role of adjunctive therapies such as anti-inflammatory agents, which are increasingly of interest in multidisciplinary infection management. Despite these limitations, the authors' approach to combining high rates of microbiological testing with careful monitoring of antibiotic use provides a model for other specialized institutions. The findings also prompt further investigation into how adjunct strategies—potentially involving lipid mediators or immune modulators—could complement antimicrobial stewardship in environments challenged by multi-drug resistance.Protocol Parameters
- Antibiotic use monitoring: Regularly track antibiotic use rates, cumulative DDDs, and cost ratios, benchmarking against regional and national data for context.
- Microbiological testing: Maintain high microbiological submission rates (>75%) for patients receiving antibacterial drugs to inform targeted therapy.
- Antibiotic selection: Prioritize susceptibility-guided therapy, particularly given high resistance rates among both Gram-negative and Gram-positive isolates.
- Resistance data analysis: Implement routine resistance trend analysis to adapt institutional antimicrobial policies and reduce selection pressure.